Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by MyKnighton Jan 10, 2020 11:00am
78 Views
Post# 30538752

RE:RE:RE:Kaly Potential

RE:RE:RE:Kaly PotentialYou underevaluate the power of shorter on an penny stock, they can bring the price to the lowest with small amount...

Their's been naked shorting(illegal) of this stock for the last year and that's why the price is so low... on a penny stock that has no revenu the shorter will win on the short time over a year now....guess who have interest at keeping it low, and who can afford people to be there all the time to bash(big Pharma).

At this point we have no friend in the big pharma...

Phase 3 will come, but money will come way before phase 3 is done, the european market will use it this year.

Their no challenge to bring the CBD GVHD to market,  it's being fast track and declare as an orphean drug, it doesn't get better then this for FDA approval process.

RE:RE:Kaly Potential

That's what worries me as well. By now, you would think the stock should have started to see a gradual appreciation in value to at least to the 0.07 to 0.10 range. I know that the future for KLY will be bright but the getting there may not be the Harlequin Romamce story that we're hoping for. IMO, the deal we are all waiting for may be complex in nature because the phase 3 trials still need to be completed, the harsh reality of the company's debt obligations, the amount of outstanding shares and the challenge of bringing a second CBD based drug to the market.
Bullboard Posts